The prospect of heritable human genome editing has provoked intense international debate. In 2018, the announcement that a researcher had used CRISPR to edit the genomes of twin girls, with the stated aim of conferring resistance to HIV, was met with widespread condemnation from the scientific community and led to calls for a global moratorium. Critics highlighted the lack of medical necessity, the absence of informed consent from the future children, and the unforeseeable long-term consequences of permanently altering the human gene pool. In response, bodies such as the World Health Organization established governance frameworks, and many countries, including the United Kingdom, have strict laws prohibiting germline editing for reproductive purposes. The debate touches on profound questions about human dignity, equity, and the acceptability of using technology to introduce genetic enhancements rather than solely addressing serious disease.
Advertisement
In the agricultural sector, gene editing occupies a different regulatory and ethical landscape. In England, the Genetic Technology (Precision Breeding) Act 2023 allows the use of gene-editing technologies that could have been achieved through traditional breeding, distinguishing them from genetically modified organisms that contain foreign DNA. This paves the way for the development of crops with improved resistance to pests and diseases, enhanced nutritional profiles, and greater resilience to climate change, potentially reducing the need for chemical inputs. Field trials of edited wheat with lower levels of asparagine, which converts to carcinogenic acrylamide when baked, and tomatoes engineered for higher vitamin D content, illustrate the practical applications. Proponents argue that precise breeding can accelerate the adaptation of agriculture to a warming world, while sceptics call for robust environmental assessments and transparent labelling to maintain consumer choice and trust.
As the technology matures, public engagement and proportionate regulation will be critical to realising its benefits while upholding societal values. The UK’s approach, involving bodies such as the Human Fertilisation and Embryology Authority and the Advisory Committee on Releases to the Environment, seeks to evaluate each application on its scientific merits and ethical dimensions through open consultation. Ongoing dialogue between researchers, policymakers, and citizens helps ensure that the direction of innovation reflects a broad consensus rather than purely commercial or technical drivers. Educational initiatives that explain the science in accessible terms are equally important, as informed debate depends on a baseline understanding of what gene editing can and cannot do. The story of CRISPR is still being written, and the choices made in the coming years will define how this powerful tool is used to shape the living world, for better or worse.
